Immuron (IMRN) Total Debt (2016 - 2023)

Immuron (IMRN) posted quarterly Total Debt of $5.4 million for Q2 2023, up 576809.8% quarter-over-quarter from $935.15 in Q4 2020.

Immuron (IMRN) Total Debt (2016 - 2023) Analysis & Trends

Immuron's Total Debt history runs 5 years deep, the most recent figure standing at $5.4 million for Q2 2023.

In Q2 2023, Total Debt changed N/A year-over-year to $5.4 million; the TTM figure through Jun 2023 stood at $5.4 million (changed N/A YoY), while the FY2020 annual figure was $935.15, down 99.52% from the prior year.
Total Debt for Q2 2023 stood at $5.4 million, up from $935.15 in the prior quarter.
The five-year high for Total Debt was $5.4 million in Q2 2023, with the low at $935.15 in Q4 2020.
The 3-year median for Total Debt is $2.0 million (2020), against an average of $2.3 million.
Peak annual rise in Total Debt reached 46.05% in 2020, while the deepest fall reached 99.52% in 2020.
Immuron's Total Debt stood at $196240.0 in 2019, then slumped by 99.52% to $935.15 in 2020, then surged by 576809.8% to $5.4 million in 2023.
Business Quant data shows IMRN's Total Debt at $5.4 million in Q2 2023, $935.15 in Q4 2020, and $2.0 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Immuron	6.81 Mn	6.78 Mn	-	-

Download Data